Although protein kinase C (PKC) activation is required for endothelial cell (EC) growth, migration, adhesion, and vessel formation, the role of individual PKC isoenzymes in these events is not defined. Because PKC␣ has been previously linked with enhanced EC migration and response to angiogenic growth factors, we characterized a specific phosphorothioate-modified 21-mer antisense PKC␣ (AS-PKC␣). AS-PKC␣ (500 nmol/L) prevented the expression of PKC␣ protein by 90% in human ECs and did not reduce the expression of any other PKC isoenzyme. AS-PKC␣ reduced human EC migration by 64% compared with its control oligonucleotide in a "scratch" wounding assay, and AS-PKC␣ reduced human EC adhesion to the extracellular matrix protein vitronectin by 18%. Phosphorylation of mitogen-activated protein kinase (extracellular signal-regulated kinase 1/2) induced by vascular endothelial growth factor was inhibited by 30% in human ECs transfected with AS-PKC␣. Compared with control, AS-PKC␣ also reduced the number of EC tubes formed in a 3D type I collagen gel assay by 37.5%. Finally, using an osmotic minipump, we infused AS-PKC␣ into mice in which myocardial infarction was induced by coronary ligation and found that the oligonucleotide was primarily taken up by intramyocardial blood vessels. Compared with the results with control oligonucleotide, AS-PKC␣ oligonucleotide inhibited the number of anti-PKC␣-stained blood vessels by 48% and reduced the total vessel number by 72% as well. In conclusion, the expression of PKC␣ is required for full EC migration, adhesion to vitronectin, vascular endothelial growth factor-induced extracellular signal-regulated kinase activation, and tube formation and is likely to be of importance in myocardial angiogenesis in vivo after ischemia. (Circ Res. 2002;90:609-616.)
A ngiogenesis, the formation of new blood vessels, is an important response to myocardial ischemia. In established blood vessels, the endothelial cells (ECs) remain in a quiescent state. After local ischemia, as well as wounding or inflammation, new blood vessels develop. 1 Protein kinase C (PKC), an intracellular serine-threonine kinase, has been reported to have a pivotal role in angiogenesis and associated processes. [2] [3] [4] PKC activation is required for EC proliferation after fibroblast growth factor (FGF)-2 stimulation, angiogenesis after vascular endothelial growth factor (VEGF) stimulation, and capillary tube formation after thrombin stimulation. 5 Multiple studies have demonstrated that PKC is not a single entity but is instead a family of at least 12 isoenzymes, 2, 6, 7 of which at least 5 are expressed in cultured human ECs 2, 8 and in angiogenic vessels in vivo. 9 The PKC isoenzymes are derived from different genes, have different activating cofactors, and vary in tissue and cellular distribution. Because of these different properties, these isoenzymes have distinct effects in cells in vitro. 10 -12 To date, no one has examined whether there is similar heterogeneity concerning the expression or role of individual PKC isoenzymes in endothelial function either in intact blood vessels or in angiogenesis in vivo, and very little work has been done regarding the detailed molecular mechanism of the effects of PKC in ECs. Such experiments in vascular cells and tissues are critical to an understanding of the role of PKC in angiogenesis. Removal of the individual PKC isoenzymes in knockout mice by homologous recombination has been reported for PKC␥, PKC␤, PKC⑀, and PKC. [13] [14] [15] [16] The phenotype of these mice has been partially assessed, and abnormalities in the neural, immunological, and endocrine systems have been noted. Although these mice are viable, suggesting that embryonal microvascular formation is relatively intact, none have been tested for disturbance in vascular function or for neovascularization after myocardial ischemia. Furthermore, even in the absence of an abnormality, it is possible that the congenital absence of an individual gene product could produce a compensatory response during development that would obscure its real pathophysiological role. We have shown that overexpression of PKC␣ in rat ECs promotes their migration, 11 but the specificity of that function for PKC␣ and whether PKC␣ has a function in angiogenesis in vivo have not been established. In the present study, we show, with the use of a PKC␣-specific antisense (AS-PKC␣) oligonucleotide, that inhibition of PKC␣ inhibits EC migration, adhesion, and extracellular signal-regulated kinase (ERK) phosphorylation and tube formation in vitro. Most important, we show in the present study that AS-PKC␣ oligonucleotide can be taken up by the intramyocardial endothelium and can inhibit neovascularization after infarction.
Materials and Methods

Cell Culture
Human ECs were isolated from umbilical veins as previously reported. 17 These human umbilical vein ECs (HUVECs) between passages 1 and 3 were grown in medium 199 (M199, Life Technologies, Inc) supplemented with 20% newborn calf serum, 5% human serum, heparin (Sigma Chemical Co), EC growth factor (Sigma), bovine brain extract, 50 U/mL penicillin G, and 50 g/mL streptomycin. Anti-PKC␣ was obtained from Transduction Laboratories.
Antisense Oligonucleotides for PKC␣
The sequence of the antisense oligonucleotides for human PKC␣ that was used in the present study is as follows: AS-PKC-␣, 5Ј-GGGAAAACGTCAGCCATGGTC-3Ј. This 21-mer was designed to hybridize with position 24 -44 of the PKC␣ mRNA. The random sequence for PKC-␣, 5Ј-GGCCTGACGTAAGATCGAGAC-3Ј (also a 21-mer oligonucleotide), was generated as a control. The AS-PKC␣ for the mouse sequence is 5Ј-AACGTCAGCCATG-GTTCCCCC-3Ј. This 21-mer oligonucleotide was designed to hybridize with both mouse and human mRNA.
Transfection of AS-PKC␣ Oligonucleotide by GenePorter
HUVECs were grown to 80% to 90% confluence in 100-mm tissue culture dishes for transfection. GenePorter (Gene Therapy Systems) was prepared in 1 mL M199 for 20 minutes. Oligonucleotides were also diluted in 1 mL M199 for 20 minutes. Then, GenePorter medium and oligonucleotide M199 were mixed gently and equilibrated for 35 minutes. Another 3 mL of M199 was added to produce a final concentration of 250 nmol/L and 500 nmol/L oligonucleotide. The cells were washed with M199 twice and treated with the GenePorter-oligonucleotide mixture for 4 hours at 37°C in 5% CO 2 . M199 with serum containing the same concentrations of oligonucleotides was added to the plates for another 4 hours. After a total of 8 hours, the medium was returned to M199 with 20% human serum. Cells were harvested 3 days later.
Immunoblotting
HUVECs were transfected with AS-PKC␣, random sequence, and control without oligonucleotides for 3 days according to the method mentioned. HUVECs were rinsed with ice-cold PBS and lysed in RIPA buffer (PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 100 g/mL phenylmethylsulfonyl fluoride, 30 L/ml aprotinin, and 1 mmol/L sodium vanadate). Total protein (20 g) from each sample was subjected to SDS-PAGE. The concentration of the protein was assessed by using the Bradford assay (Bio-Rad Laboratories) before loading. After transfer, the blotting membrane was incubated for 1 hour at room temperature in Tween 20 -PBS buffer with 5% (wt/vol) dry milk to block nonspecific binding sites. Then, the membrane was incubated with primary antibody at a 1:1000 or 1:2000 (␣-tubulin) dilution in PBS containing 0.05% Tween 20 with 5% (wt/vol) dry milk. The protein levels were quantified by densitometry with Bio-Rad gel molecular analysis software. The membrane was then stripped with stripping buffer and reblotted with monoclonal anti-␣-tubulin antibody (Sigma) for protein loading control.
Endothelial "Wounding" Assays to Assess Migration
HUVECs were transfected with AS-PKC␣ oligonucleotides or their controls for 3 days. Cells were then treated with trypsin and cultured on 6-well plates in HUVEC medium until confluent. The monolayers were wounded by scraping Ϸ600 m with a 1-to 200-L pipette tip. The distance of the gap was measured under a ϫ4 phase objective of a light microscope and captured with a Sony video graphic system (monitor, PVM97; printer, UP890 MD).
Adhesion Assay
Before carrying out the adhesion assay, HUVECs were transfected with AS-PKC␣ or control for 3 days. Cell adhesion was then performed as previously described with minor modifications. 18, 19 Briefly, 96-well polystyrene plates were coated with 10 g/mL vitronectin in PBS. HUVECs were harvested and suspended in M199 (GIBCO-BRL) medium with 2% BSA at a concentration of 10 6 cells/mL. Cells (50 000) were added to each well of a 96-well plate. After incubation at 37°C for 1 hour, nonadherent cells were removed with gentle washing by sterile PBS. The remaining cells in wells of control plates without oligonucleotide treatment were used as the standard (100%). Quantification of cell attachment was determined by staining the cells with 0.5% crystal violet in 20% methanol, washing the cells, and then eluting the dye with 0.1 mol/L sodium citrate, pH 4.2, and measuring the absorbency at 595 nm.
ERK Activity Assay
HUVECs were first transfected with AS-PKC␣ oligonucleotides, random oligonucleotides, or control without oligonucleotides for 3 days. Then, HUVECs were grown in 1% serum-starvation medium at 37°C for 18 hours. Afterward, cells were stimulated by VEGF or FGF-2 in serum-free medium for specified times. Phosphorylation of ERK1/2 was detected by immunoblotting with the use of polyclonal phospho-ERK12 antibody (New England Biolabs) with horseradish peroxidase-conjugated goat complexes on nitrocellulose, which were visualized by an enhanced chemoluminescence detection system (Amersham). Density of the bands was analyzed by Bio-Rad gel molecular analysis software.
Cell Proliferation Analysis
Cell proliferation was determined by counting the cells with a Coulter counter. Subconfluent cells were synchronized in medium without EC growth factor for 24 hours and then seeded at 2.0ϫ10 4 per 35-mm plate in 2 mL of medium without EC growth factor or with 20 ng/mL VEGF or 20 ng/mL basic FGF (bFGF). After being cultured for indicated periods, the HUVECs were washed with PBS, treated with trypsin, and suspended in the medium for counting.
3D In Vitro Tube Formation
A 3D collagen gel assay for angiogenesis was performed in vitro as described. 20 Briefly, rat tail collagen type I from Upstate Biotech Inc (1.75 mg/mL) and human fibronectin at a final concentration of 90 g/mL were mixed with 1.8 mg/mL NaHCO 3 , 1ϫ M199, and 0.075 mol/L HEPES and placed on ice. HUVECs were then mixed with the collagen mixture at a final concentration of 2ϫ10 6 cells/mL. Approximately 400 L of the above cell-collagen mixture was added to a 12-well plate and incubated for 10 minutes after the addition of 1 mL HUVEC medium. After 2 days, tube length was measured by microscope. To confirm that tubes were actually formed in the collagen gel, the gels were fixed and embedded in paraffin and cut into 5-m sections and stained with hematoxylin and eosin. Tubular structures complete with lumina that were formed in the collagen gel were identified under high-magnification microscopy.
In Vivo Experiments
Eight-to 9-week-old male C57BL/6 mice were used in all experiments. The day before the induction of myocardial infarction, the mice were anesthetized with methoxyflurane, and a miniosmotic pump (Alzet) was implanted between the scapulae to infuse the oligonucleotides into the mice. The rate of infusion of the pump was 0.25 L/h for 14 days. Each oligonucleotide was diluted in saline solution to a defined concentration; the dosage for AS-PKC␣ and random sequence oligonucleotides was 1 or 2 mg/kg per day for 14 days.
Myocardial infarction was created by ligating the left coronary artery in the mouse heart at open surgery as described. 21 Briefly, the mice were anesthetized initially with methoxyflurane and ventilated with a rodent respirator attached to a nose cone. The heart was exposed through a left-sided thoracotomy at the 4th intercostal space. The myocardial infarction was produced by permanent ligation of the left coronary artery with an 8.0 monofilament polypropylene suture with a tapered needle. The suture was passed underneath the left coronary artery 1 to 3 mm from the tip of the left atrium. Successful ligation of the coronary was identified by the regional discoloration resulting from ischemia. The chest was closed; after 14 days, the mice were euthanized, and the hearts were taken for immunohistochemistry to measure the PKC gene expression and vessel formation.
Immunohistochemical Staining
The mice receiving either AS-PKC␣ oligonucleotide or control were euthanized 14 days after myocardial infarction. The heart was then removed, fixed in 4% paraformaldehyde, and embedded in paraffin, and 4-m sections were stained with hematoxylin and eosin and monoclonal antibody against PKC␣ or with mouse platelet-EC adhesion molecule-1 (PECAM-1, BD Pharmingen). Immunohistochemical experiments were performed by using the Vectastain Elite ABC kit (Vector Laboratories). Negative controls were performed by omitting the primary antibodies. Double staining of sections was carried out by first staining the sections for PKC␣ and subsequently staining them for PECAM-1, as detailed above. The results were viewed with the use of a Nikon microscope and were photographed by a Nikon digital camera. The numbers of vessels in the sections were counted, and the mean and probability values were calculated by using the Student t test. Ten visual fields were quantified in sites of active angiogenesis in three different areas. For each group of mice, the ratios of the number of anti-PKC␣-staining vessels to the total number of vessels were also calculated.
Statistical Analysis
Data are presented as meanϮSE. Significant differences were determined by the Student t test (PϽ0.05).
Results
Specificity and Efficacy of AS-PKC␣
To determine the specificity of the AS-PKC␣ oligonucleotide, the oligonucleotide, a random sequence oligonucleotide, and control were transfected into HUVECs by using the GenePorter reagent at 250 nmol/L and 500 nmol/L (final concentration). A 5Ј-fluorescein-labeled AS-PKC␣ was also used to test the transfection efficiency, which was found to be nearly 100%. Western blot analyses were performed to measure level of the PKC␣ protein expression level in these treated cells. Figure 1 shows experimental results at an oligonucleotide concentration of 500 nmol/L. The results show that AS-PKC␣ inhibited PKC␣ protein expression by 90% and 50% at 500 nmol/L and at 250 nmol/L concentrations, respectively. At 500 nmol/L, AS-PKC␣ did not inhibit the other nontargeted PKC isoenzymes. Thus, the AS-PKC␣ synthesized in these experiments is a specific and potent inhibitor of PKC␣.
Inhibition of EC Migration by AS-PKC␣
To determine the role of PKC␣ in the migration of ECs, HUVECs were first transfected with AS-PKC␣ oligonucleotides and controls for 3 days, and then the transfected cells were subcultured in 6-well plates at a 5ϫ10 5 cell density. The endothelial wounding assay was performed to test cell migration. The result is shown in Figure 2 ; AS-PKC␣ inhibited HUVEC migration by 64% compared with control. These experiments show that PKC␣ is required for full EC migration.
Inhibition of EC Adhesion by AS-PKC␣
EC adhesion via the ␣ v ␤ 3 and ␣ v ␤ 5 integrins is a critical step in angiogenesis. To determine the effect of PKC␣ on the function of these integrins, we measured the ability of ECs to adhere to the matrix protein vitronectin. Cells transfected for 3 days were seeded on 96-well plates. The results from the experiments are shown in Figure 3 . Compared with control, AS-PKC␣ inhibited EC adhesion; adhesion of the cells treated with AS-PKC␣ decreased by 18% compared with that seen with the untreated and control oligonucleotide-treated cells. Thus, these experiments demonstrate that inhibition of PKC␣ may affect adhesion to vitronectin, a process important in angiogenesis.
Effect of AS-PKC␣ on ERK Activity
In preliminary experiments, we found that ERK1/2 activity increased after stimulation by 50 ng/mL VEGF or 50 ng/mL FGF-2, with a peak at 20 minutes, followed by a gradual decline in activity. Thus, the 20-minute point was chosen for use in subsequent ERK1/2 experiments (Figure 4 ). ECs were transfected with AS-PKC␣ and random sequence oligonucleotides or no oligonucleotide control for 3 days. Then, ECs were stimulated by VEGF or FGF-2. The ERK1/2 activity was measured by immunoblotting. We found that AS-PKC␣ inhibited 30% of the phosphorylation of ERK1/2 induced by VEGF but not any of the ERK phosphorylation resulting from FGF-2. Thus, PKC␣ appears to contribute to VEGF-induced ERK phosphorylation, with the majority of this phosphorylation being induced by other VEGFstimulated mediators. Figure 5 shows the result on AS-PKC␣ cell proliferation in different conditions. In Figure 5A , HUVECs grown in the medium without endothelial growth supplements exhibited no changes with AS-PKC␣ compared with control. In contrast, the growth rate of HUVECs treated with 20 ng/mL VEGF was inhibited 18% to 20% by AS-PKC␣ ( Figure 5B ). AS-PKC␣ did not affect the growth rates, which were similar in HUVECs stimulated by 20 ng/mL bFGF ( Figure 5C ).
Effects of AS-PKC␣ on Cell Proliferation
Tube Formation
To examine further the function of PKC␣ in tube formation, AS-PKC␣ transfected into ECs was assayed in a 3D collagen gel experiment. Figure 6 shows that compared with control, AS-PKC␣ oligonucleotide inhibited 3D collagen tube formation by 37.5% in complete medium ( Figure 6B ). In Figure 6C , AS-PKC␣ slightly inhibited tube formation by 25% compared with control in HUVECs stimulated by 50 ng/mL VEGF. Thus, PKC␣ appears to be important mediator for tube formation as well as EC migration in vitro.
In Vivo Experiments
On the basis of these in vitro experimental results, we tested the importance of AS-PKC␣ in angiogenesis in vivo. In initial experiments, we tested the feasibility of delivering AS-PKC oligonucleotides to intramyocardial blood vessels with an implanted osmotic minipump. In this experiment, an FITClabeled AS-PKC␣ oligonucleotide was loaded into a microosmotic pump and implanted subcutaneously between the scapulae of the mice. After 10 days, the mice were euthanized, and the hearts were examined to determine whether the oligonucleotide entered the heart microvasculature by look- ing at a heart tissue sample under a fluorescence microscope. These results (shown in Figure 7 ) indicated that PKC␣ could circulate to the microvasculature of the heart. Figure 8A shows the immunohistochemical staining for PKC␣ and staining for PKC⑀ and PKC␤1 for the AS-PKC␣-treated sample to determine the specificity of AS-PKC␣. M␣ is the mouse sample treated with AS-PKC␣ oligonucleotide designed to block both human and mouse PKC␣ protein synthesis. PKC␣ and PECAM-1 double staining are shown in Figure 8B at 2 mg/kg per day of AS-PKC␣ oligonucleotide or control. In Figure 8A , PKC␣ gene expression is shown to be inhibited significantly compared with the saline and random sequence controls in heart tissue samples at the oligonucleotide dosage of 2 mg/kg per day. To further establish the identity of the vessels, double staining was performed, and the results are shown in Figure 8B . The vessels stained brown indicate those that are double-stained with black (anti-PKC␣) and red (anti-PECAM-1). In Figure 8C , the inhibitory effect of antisense PKC␣ is represented as the bar graph of the total vessel number in the three groups of mice. Figure 8C demonstrates that AS-PKC␣ inhibited vessel formation by 72%. In Figure 8D , the effect of the inhibition of AS-PKC␣ is present as the ratio of the anti-PKC␣-stained vessel number to the total vessel number in each group itself. The ratios for saline-treated and random sequence-treated mouse hearts are 0.97Ϯ0.01 and 0.99Ϯ0.01, respectively; however, in the antisense-treated mouse heart sample, the ratio is 0.51Ϯ0.07 (all are meanϮSEM, nϭ5). Thus, compared with control, AS-PKC␣ oligonucleotide inhibited PKC␣ expression by 48%. Staining results show the dosage-dependent inhibition to PKC␣ expression. At 1 mg/kg body wt per day, there are no inhibitions for PKC␣ expression (data not shown). The other PKC isoenzymes were not inhibited by AS-PKC␣ oligonucleotide.
Discussion
The major finding of the present study is that PKC␣ is a necessary component of the signal transduction pathway that is involved in EC migration, adhesion, and tube formation in vitro and angiogenesis after myocardial ischemia. In addition, the present study also demonstrated that delivery of an AS-PKC␣ oligonucleotide could selectively inhibit PKC␣ gene expression in vivo, along with preventing myocardial vessel formation, in a murine model of myocardial infarction.
PKC is a family of at least 12 kinases, some of which have been shown to be essential for EC growth and angiogenesis. Previously, we have demonstrated that overexpression of PKC␣ in rat ECs promotes migration, a key component of angiogenesis, whereas overexpression of PKC␦ to a similar degree does not affect migration but, instead, slows cell cycle progression by delaying the passage of the cells through S phase. 11 PKC overexpression has neither of these effects. 12 These findings suggest that PKC isoenzymes phosphorylate different substrates in these cells with different physiological effects. There are several limitations in the interpretation of overexpression studies because of the potential lack of specificity. Thus, we chose to inhibit an individual PKC isoenzyme to determine its effects on angiogenesis after ischemia. The results of the present study demonstrate that AS-PKC␣ inhibited EC migration significantly, thus confirming our previous conclusion 11 and expanding those findings markedly to show implications for angiogenesis in vivo. ERK1/2, from the mitogen-activated protein kinase (MAPK) family, is a key component of the cascade of intracellular signaling pathways that lead to EC growth, migration, and adhesion. Previous studies have shown that inhibition of PKC⑀ in ECs prevents MAPK (ERK) activity in response to shear stress. 22 In the present study, AS-PKC␣ oligonucleotide inhibited a small portion of ERK-1 activity induced by VEGF but not by FGF-2, suggesting that PKC␣ is involved in the pathway to ERK1/2 induced by VEGF. Others have found that the mitogenic effects of VEGF on ECs are mediated by PKC␣. 23 In the present research, the slight inhibitory effects of AS-PKC␣ on VEGF-stimulated HUVEC proliferation and collagen tube formation are consistent with the reduction in ERK activity and thus confirm previous results. 23 In other studies, Kent et al 24 also demonstrated that, although FGF-2 increased overall PKC activity, the changes in cellular function were correlated with changes in Ca 2ϩindependent PKC isoenzymes rather than PKC␣. The results in the present study confirm that AS-PKC␣ oligonucleotide inhibited a component of the ERK1/2 activity induced by VEGF but not by FGF-2 and that it also inhibited the EC adhesion to vitronectin. Previously, we had shown that overexpressing PKC␣ did not affect vitronectin adhesion, 11 raising the possibility that such adhesion is regu-lated by a threshold amount of PKC␣, which is not achieved in AS-PKC␣-treated ECs. Because of the association of ␣ v ␤ 5 with VEGF-mediated angiogenesis (in contrast to the association of FGF-2 with ␣ v ␤ 3 ), 25 we speculate that the PKC␣ isoenzyme is activated after ␣ v ␤ 5 adhesion to vitronectin.
Because of the lack of specific chemical inhibitors for PKC isoenzymes, assessment of the function of individual PKC isoenzymes in vivo has not been definitive. In cardiovascular research, antisense oligonucleotides (predominantly phosphorothioate oligodeoxynucleotides) have been used in ischemia and other disease models. For example, antisense oligodeoxynucleotides inhibited PKC␣ expression in porcine aortic ECs and were used to demonstrate that the Ca 2ϩ antagonist nifedipine influences ischemia-induced endothelial permeability via PKC␣ inhibition. 26 In addition, antisense oligonucleotides have also been successfully used to inhibit PKC protein synthesis by vascular smooth muscle cells. 27, 28 The advantage of antisense strategy is its high selectivity 29 ; a sequence of 15 bases is sufficient to ensure the required selectivity. 30 The present studies show the feasibility of this method to investigate gene expression in the myocardial vascular tube. An antisense oligonucleotide to PKC␣ has been used in a phase I study in patients with cancer 31 and was found to prevent tumor growth in vivo, but the mechanism for this effect is not known. In the present study, the dosages used in the clinical trial were used as guides for treatment after myocardial infarction. Because it used a myocardial infarction angiogenesis model to study the function of AS-PKC␣, the present study cannot be compared directly with that clinical observation, but it suggests that one cause of that effect may be the inhibition of angiogenesis. The present study treated mice for 14 days to maintain the concentration of antisense oligonucleotide circulating in the heart of each mouse and, thus, to prolong the inhibition of PKC␣. The length of time necessary for treatment likely remains to be established. In summary, our determination that inhibition of PKC␣ gene expression was feasible in vivo and could prevent vessel formation in an animal model is well correlated with the effects of this gene product in vitro. Thus, we conclude that PKC␣ is a key mediator of angiogenesis and a potential target in the development of selective agonists (cardiovascular disease) or antagonists (cancer). Finally, the method used in the present study will provide a useful tool for investigating the roles of individual PKC isoenzymes in postinfarction collateral formation in vitro and in vivo. 
